Zynex, Inc. Stock Plummets to New 52-Week Low at $1.13

Zynex, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 1.13 on October 31, 2025. This significant decline marks a staggering 87.86% drop in the stock's performance over the past year, contrasting sharply with the S&P 500's gain of 19.89% during the same period.
The company's market capitalization stands at approximately USD 46 million, reflecting its microcap status. Zynex has faced considerable financial difficulties, reporting negative results for the last nine consecutive quarters. The pre-tax profit for the latest quarter was recorded at USD -11.12 million, a decline of 336.56%. Additionally, the operating cash flow for the year reached a low of USD -7.19 million.

With a return on equity of -2,272.96% and a price-to-book ratio of 36.52, Zynex's financial metrics indicate a challenging environment. The stock's 52-week high was previously noted at USD 9.33, highlighting the extent of its recent downturn. As Zynex navigates these financial hurdles, its performance continues to be closely monitored within the industry.